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Macrophage-dependent IL-1b production induces
cardiac arrhythmias in diabetic mice
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Diabetes mellitus (DM) encompasses a multitude of secondary disorders, including heart
disease. One of the most frequent and potentially life threatening disorders of DM-induced
heart disease is ventricular tachycardia (VT). Here we show that toll-like receptor 2 (TLR2)
and NLRP3 inflammasome activation in cardiac macrophages mediate the production of IL-1b
in DM mice. IL-1b causes prolongation of the action potential duration, induces a decrease in
potassium current and an increase in calcium sparks in cardiomyocytes, which are changes
that underlie arrhythmia propensity. IL-1b-induced spontaneous contractile events are
associated with CaMKII oxidation and phosphorylation. We further show that DM-induced
arrhythmias can be successfully treated by inhibiting the IL-1b axis with either IL-1 receptor
antagonist or by inhibiting the NLRP3 inflammasome. Our results establish IL-1b as an
inflammatory connection between metabolic dysfunction and arrhythmias in DM.
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S
terile inflammation usually resolves an initial insult1, but
sometimes persists, as in the case of metabolic dysfunction.
This inflammation has been implicated in the pathogenesis
of several metabolism-associated diseases and represents a
putative link between diabetes mellitus (DM)1–4 and secondary
heart disease.
In diabetic patients, cardiomyopathy and its main
complication, ventricular arrhythmias, are the leading cause of
death5,6. In fact, diabetic patients show higher frequency of fatal
ventricular arrhythmias and sudden cardiac death7–10. Moreover,
these patients present both QT and corrected QT interval (QTc)
prolongation due to increased ventricular action potential
duration (APD), which predisposes to arrhythmogenesis7,8,11.
The main mechanisms underlying these diabetic arrhythmias are
still unknown, but we hypothesized that sterile inflammation
triggered by hyperglycemia is the main pathophysiological
mechanism. In fact, hyperglycemia upregulates toll-like receptor
2 (TLR2) expression in monocytes12 leading to continuous
interleukin (IL)-1b production, which in turn has been implicated
as a mediator of the deleterious effects of hyperglycemia13.
Additionally, the presence of this cytokine has been reported in
type 1 diabetic hearts14.
The nucleotide-binding domain and leucine-rich repeat
containing protein (NLRP) family of cytosolic pattern recognition
receptors has a critical role in promoting sterile inflammation.
Recognition of danger signals released from failing or
malfunctioning cells, leading to production of mature IL-1b, is
a key event in this process15. TLR agonists can transcriptionally
induce the expression of NLRP3 and pro-IL-1b16. NLRP3
oligomerizes with the adaptor molecule ‘apoptosis-associated
speck-like protein containing a CARD domain’ (ASC) in response
to different signals1,17,18. NLRP3 and ASC subsequently recruit
the cysteine protease pro-caspase-1 to generate a caspase-1-
activating platform, known as the inflammasome1,19. The
inflammasome then promotes caspase-1-dependent proteolytic
cleavage of pro-IL-1b into mature IL-1b. However, the effects
of IL-1b on target organs, which are involved in the pathogenesis
of DM, are still to be unravelled.
Here we investigated the role of sterile inflammation in the
induction of arrhythmias in DM. We show that IL-1b produced
by DM heart macrophages targets cardiomyocytes to induce
cardiac arrhythmias. Using a multi methodological approach,
we demonstrate how TLR2 and NLRP3 inflammasome activation
in macrophages mediate the production of IL-1b. Our results
indicate that the inflammatory response to the metabolic
dysfunction in DM generates cardiac arrhythmias. Our study
also reveals a novel treatment option of DM-related arrhythmias
by using either an IL-1b receptor antagonist (anakinra) or a
NLRP3 inhibitor (MCC-950).
Results
TLR2 is required for diabetes-induced arrhythmias.
Hyperglycemia upregulates TLR2 expression in monocytes12 and
TLR2 participates is cardiac sterile inflammation in a number of
situations20,21. To investigate the involvement of the TLR2-IL-1b
axis in cardiac electrical activity, DM was induced in wild-type
(WT) and Tlr2 / mice (Fig. 1a). Despite similar high
blood glucose levels (inset Fig. 1a), the diabetic Tlr2 / group
presented shorter QT (Fig. 1b and Supplementary Fig. 1a,b) and
QTc intervals, when compared with diabetic WT mice (Fig. 1c).
In diabetic WT mice cardiac action potential (AP) displayed
slower repolarization, when compared with non-diabetic WT
mice, while in diabetic Tlr2 / mice AP duration (APD) was
similar to non-diabetic mice (Fig. 1d,e). The absence of TLR2
drastically reduced the susceptibility to cardiac arrhythmias after
caffeine and dobutamine (Caff/Dobu) challenge in diabetic mice
(Fig. 1f,g), which were not detected in non-diabetic animals
(Supplementary Fig. 1d). These results were gender-independent,
since these key findings were very similar in females
(Supplementary Fig. 2). Cardiac relative mass and left
ventricular morphology and function were preserved in all
groups (Supplementary Fig 3a–e). No differences were observed
in QRS duration or in cardiac fibrosis among experimental
groups (Supplementary Fig. 1c and 3f,g). In a similar manner
compared with an earlier study22, we have observed a trend
towards lower insulin levels in Tlr2 / diabetic compared
with Tlr2 / non-diabetic mice (unpaired t-test; P¼ 0.07)
(Supplementary Table 1), although the difference did not reach
statistical significance. In addition, the Tlr2 / diabetic mice
showed insulin levels similar to WTþDM mice suggesting that:
(i) the anti-inflammatory protection afforded by the lack of TLR2
was not enough to protect the streptozotocin-impaired pancreatic
function; and (ii) the lack of electrophysiological changes
observed in this KO mice could be not related to changes in
insulin levels. TLR2 activation has a key role in metabolic and
cardiac diseases and its presence is required to trigger IL-1b
production in different animal models23. We observed that
diabetic Tlr2 / mice have lower systemic (Fig. 1h) and local
(heart) (Fig. 1i,j and Supplementary Fig. 4) concentrations of
IL-1b than diabetic WT mice. No differences were observed in
the cardiac IL-1b messenger RNA expression between WT
and Tlr2 / (Supplementary Fig. 5). Collectively, these data
demonstrate that TLR2 contributes to IL-1b production, electrical
disturbances and arrhythmias in a mouse model of DM.
IL-1b induces cardiac electrical vulnerability. Since the lack of
TLR2 expression not only prevents AP prolongation and
electrical vulnerability but also the DM-induced rise in local and
systemic levels of IL-1b, we hypothesized that IL-1b is involved in
these cardiac changes. We, therefore, investigated whether 24 h
exposure to IL-1b is able to induce cardiac functional changes by
measuring APD, ion currents and Ca2þ handling in isolated rat
cardiomyocytes. First, we found that IL-1b prolongs the APD
(Fig. 2a–c), then we investigated its effect on a key repolarizing
potassium current, namely the transient outward potassium
current (Ito). Incubation of isolated ventricular cardiomyocytes in
the presence of IL-1b, using pathophysiological levels
(60 pgml 1, for more details please see Fig. 1h), for 24 h resulted
in a B35% reduction of this current (Fig. 2d–f).
Several types of arrhythmia have been attributed, at least in part,
to enhanced diastolic Ca2þ leak from the sarcoplasmic reticulum
(SR)24. Using confocal imaging, we examined the impact of IL-1b
on SR Ca2þ leak by monitoring Ca2þ spark properties, which
were increased after IL-1b exposure (Fig. 2g,h,j and Supplementary
Fig. 6b–f). Accordingly, a modest but significant negative post-rest
variation in the SR Ca2þ content was observed only in IL-1b-
treated myocytes (Fig. 2i). However, the SR Ca2þ content was not
significantly different in cells incubated for 24 h in the presence
and absence of IL-1b (Supplementary Fig. 6g). Rest does not
typically affect the SR Ca2þ load, unless Ca2þ efflux by the
Naþ /Ca2þ exchanger (NCX) is enhanced25,26. In this case,
however, one would expect a greater ratio of the rate constants of
[Ca2þ ]i re-uptake upon application of 10mM caffeine or by
electrical stimulation27, in which Ca2þ clearance from the cytosol
is dependent mainly on the NCX and the SR Ca2þ ATPase plus
NCX, respectively28. However, neither the rate constants of Ca2þ
re-uptake/efflux (not shown), nor their ratio (Supplementary
Fig. 6h) was significantly changed by IL-1b incubation, which
indicates that the IL-1b-induced diastolic leak is not accompanied
by stimulation of NCX-mediated Ca2þ efflux.
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Figure 1 | TLR2 regulates cardiac electrical parameters and incidence/severity of DM-induced arrhythmias. (a) Experimental protocol: diabetes (DM)
was induced in wild-type mice (WT) and toll-like receptor 2 knock-out mice (Tlr2 / ) by five daily i.p. injections of streptozotocin (STZ) (50mg kg 1)
and several parameters were analysed 60 days after the beginning of the protocol. Inset shows serum glucose levels of all experimental groups at day 60
(n¼WT: 10; Tlr2 / : 10; WTþDM: 10; Tlr2 / þDM: 10). (b) Representative ECG traces of DM mice highlighting QT interval prolongation only in the
WTgroup. (c) Corrected QT (QTc) interval duration (n¼WT: 10; Tlr2 / : 5; WTþDM: 10; Tlr2 / þDM: 4). (d) Representative action potential (AP)
traces from the endocardial layer of left ventricle strips at 300ms basic cycle length (BCL) stimulation. (e) AP duration at 90 per cent of repolarization
(APD90) in different BCL (n¼WT: 7; Tlr2 / : 6; WTþDM: 8; Tlr2 / þDM: 6). (f) Representative ECG traces during arrhythmia vulnerability test
induced by caffeine and dobutamine (Caff/Dobu) showing ventricular tachycardia (VT - see red line) in WTþDM mice and a normal ECG in Tlr2 /
þDM. (g) Score quantification of arrhythmia incidence and severity (n¼WT: 6; Tlr2 / : 6; WTþDM: 7; Tlr2 / þDM: 7). (h–j) Serum and local
(heart) protein levels of IL-1b after 60 days of DM induction in experimental groups. Graph represents three (serum) and two (hearts, n¼6 mice per
group) independent experiments performed in duplicate. The results are expressed as mean±s.e.m. Scatter plot shows values from individual mice, where
horizontal bars represent means and error bars, s.e.m. * and ** represent respectively Po0.05 and Po0.01 versus WTþDM, (unpaired t-test). # and ##
represent, respectively, Po0.05 and Po0.01 versus WTþDM (Bonferroni’s post test following two-way ANOVA).
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Figure 2 | IL-1b induces electrical abnormalities in rat and human cardiac cells. (a) Experimental protocol. Cardiac muscle strips from rat hearts
were incubated for 24 h with IL-1b (10 ngml 1) with or without IL-1 receptor antagonist (IL-1ra: 100 ngml 1) and electrical function was assessed.
(b,c) Representative action potential (AP) traces from left ventricle endocardial at 300ms basic cycle length (BCL) before and after incubation with IL-1b
(left panel), and APD90 data from endocardial layer of left ventricular strips (right panel) (n of cells¼Control: 10; IL-1b: 14; IL-1bþ IL-1ra: 12; 4 hearts).
(d) Experimental protocol: Hearts from rats were enzymatically dissociated and isolated cardiomyocytes were incubated for 24 h with IL-1b.
(e,f) Representative traces (left panel) and current versus voltage (IV) curves (right panel) of Ito current after exposure to IL-1b (n of cells¼Control: 17;
IL-1b (60 pgml 1): 5; from three hearts). (g) Quantification of calcium spark frequency and (h) spark fluorescence amplitude (F/F0) (n of cells¼Control:
11; IL-1b 20; cells from three hearts). (i) Post-rest decrease in sarcoplasmatic reticulum (SR) calcium content expressed as variation as per cent of the
steady-state content per min rest (n of cells¼Control: 19; IL-1b 18; four hearts). (j) Representative images of calcium spark before and after incubation or
not with IL-1b. (k) Representative traces of field potential in human iPS-derived cardiomyocytes highlighting effect of IL-1b on the field potential duration
(FPD. (l,m) FPD and its variation in individual cell preparations before and after 24 h of incubation with control solution or IL-1b (10 ngml 1) (n¼Control:
6; IL-1b: 7; from three independent experiments). The results are expressed as mean±s.e.m. Scatter plot shows values from individual cell preparations,
where horizontal bars represent means and error bars, s.e.m. # represents Po0.05 (Bonferroni’s post test following one-way ANOVA). ** and *** represent,
respectively, Po0.01 and Po0.001 (Bonferroni’s post test following two-way ANOVA). w and ww represent, respectively, Po0.05 and Po0.01(unpaired
t-test).
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We next investigated whether the reported IL-1b effects on
cardiac electrical properties in rodents could be also observed in
human cardiomyocytes. We, therefore, tested IL-1b effects in
human induced pluripotent stem-cell derived cardiomyocytes
(hIPS-CM) using field potential duration (FPD) measurement.
Our experiments revealed longer FPD on IL-1b treated hIPS-CM,
when compared with untreated hIPS-CM (Fig. 2k–m).
Thus, IL-1b decreases Ito current, prolongs repolarization, and
increases diastolic SR Ca2þ leak, providing a cellular substrate for
triggered arrhythmogenic activity.
IL-1b and pCaMKII/oxiCaMKII induce arrhythmias. Ca2þ
and calmodulin-dependent protein kinase II (CaMKII) have been
implicated in diabetes-associated arrhythmias29,30 and recent
evidence indicates that MyD88 inflammatory signalling leads to
CaMKII oxidation and activation31. We, therefore, explored
CaMKII activity upon exposure of cardiac strips to 10 ngml 1 of
IL-1b for 24 h and then freeze-clamped the tissue for western
blotting. IL-1b effectively promoted CaMKII oxidation
(oxiCaMKII) and phosphorylation (p-CaMKII) (Fig. 3a,b and
Supplementary Fig. 7). To determine whether mere exposure to
IL-1b is sufficient to generate a pro-arrhythmogenic substrate,
ventricular myocytes were incubated for 24 h with IL-1b and the
number of spontaneous contractile events (NSE), an index of
cellular arrhythmic activity, was measured after pacing the cells
during 10min at either 0.5 or 3Hz. Cells incubated in the absence
of IL-1b (control) had only sporadic NSE, whereas they were
significantly enhanced by IL-1b (Fig. 3c,d). Importantly, the
IL-1b-induced NSE were largely reduced when tissue was
pretreated with 2.5 mmol l 1 of the CaMKII inhibitor, KN93
(Fig. 3c). Since it is well accepted that KN-93 has numerous off
target actions, including ionic currents with potential relevance to
the observed arrhythmia phenotypes, a set of experiments were
conducted using, the KN93 inactive analog KN92, either in the
absence or presence of IL-1b (Fig. 3d). While KN92 alone did not
significantly affect the NSE, the combination of KN92þ IL-1b
induced an increase in the number of NSE. In order to confirm
the role of CaMKII as a mediator of the increased NSE, another
set of experiments were conducted using cardiomyocytes from
mice with genetic CaMKII inhibition by cardiac-specific
expression of autocamtide 3 inhibitory peptide (AC3-I)
mimicking a conserved sequence of the CaMKII regulatory
domain and their respective controls, which have an scrambled
version of AC3-I (autocamtide 3 control peptide (AC3-C))32.
Such as shown in Fig. 3c,d, AC3-C cells exposed to IL-1b
presented a higher number of NSE compared with the same cell
type under control condition. Conversely, the AC3-I cells exposed
to IL-1b did not show a significant increase in NSE (Fig. 3c,d and
Supplementary Fig. 6). Additionally, in order to elucidate whether
the CaMKII inhibition also could have a key role in human cells,
hIPS-CM were exposed to IL-1b in the absence or in the presence
of a selective CaMKII inhibitor (autocamtide—2—related
inhibitory peptide (AIP)). In this setting, it was observed that
the CaMKII inhibition was able to prevent the IL-1b-induced
longer FPD in hIPS-CM (Fig. 3e,f).
Collectively these data demonstrated the key role-played
by CaMKII activation in the electrophysiological changes induced
by IL-1b.
IL-1b production by TLR2-activated macrophages in heart tissue.
In order to demonstrate that TLR2 stimulation was
involved in IL-1b release, we incubated left ventricular
myocardial strips from healthy rats for 24 h with a TLR2/1
agonist (Pam3) (Fig. 4a); these strips are known to contain other
cell types besides CMs, such as immune cells. Pam3 incubation
yielded a significant increase in cardiac IL-1b concentration
(Fig. 4b). Since IL-1b secretion can be triggered by TLR2
activation in macrophages23, a group of animals was previously
treated with liposomes containing clodronate-L (dichloro-
methylene diphosphonate (Cl2MDP)), a chemical agent that
induces macrophage apoptosis33, in order to test whether
macrophages are the source of IL-1b production induced by
TLR2 activation. As a control condition, liposomes containing
PBS were used (Fig. 4a,b). Stimulation of myocardial strips from
macrophage-depleted animals with Pam3 resulted in significantly
lower IL-1b amounts compared with those from non-
macrophage-depleted healthy hearts (PBS liposome condition)
(Fig. 4b). In addition, stimulation of the left ventricular wall for
24 h with either Pam3 or IL-1b promoted similar cardiac AP
prolongation, an effect prevented by simultaneous incubation
with IL-1receptor antagonist (Figs 2a–c and 4c–e). Macrophage
depletion prevented not only the rise in IL-1b (Fig. 4b),
but also the AP prolongation seen after Pam3 stimulation
(Fig. 4f,g). Conversely, the hearts obtained from animals
pre-treated with liposome-PBS (control condition) showed
longer AP repolarization after 24 h incubation with Pam3
(Fig. 4f,g). Taken together, these results demonstrate that the
APD prolongation induced by TLR2 stimulation is mediated by
cardiac macrophages through IL-1b production.
Tlr2 / have lower MHCIIhigh and NLRP3 macrophage
content. Recent publications described the importance of
MHCIIhigh cardiac macrophages for IL-1b secretion in different
cardiac diseases34. We assessed the presence of macrophage
subsets in hearts of diabetic mice (Fig. 5a–c and Supplementary
Fig. 8). The percentage of MHCIIhigh macrophages was reduced
in diabetic Tlr2 / mice compared with diabetic WT mice,
despite a similar percentage in the hearts of non-diabetic Tlr2 /
 and WT animals, indicating that, in the absence of TLR2,
diabetic mice display a reduction in the cardiac macrophage
subpopulation responsible for the IL-1b production. TLR2
expression in cardiac macrophages was similar in non-diabetic
and diabetic WT mice (Supplementary Fig. 9).
Several groups have described the importance of NLRP3
inflammasome activation in macrophages for IL-1b maturation/
production in DM3,35. Therefore, we also investigated NLRP3
content (red) in resident macrophages (F4/80 marker, green)
present in cardiac tissue from WT and Tlr2 / control and
diabetic mice. We observed lower NLRP3 content in
macrophages from diabetic Tlr2 / mice compared with
macrophages from diabetic WT mice (Fig. 5d,e), indicating that
NLRP3 expression is upregulated by TLR2 signalling.
Activation of NLRP3 inflammasome and arrhythmias in DM.
As we have shown that cardiac macrophages produce IL-1b and
upregulate NLRP3 expression in response to TLR2 stimulation
promoted by DM, we tested whether the NLRP3 inflammasome is
involved in the DM-induced cardiac electrical disturbances and
susceptibility to arrhythmias. For this purpose, DM was induced
in Nlrp3 / and Casp1 / as well as in WT mice (Fig. 6a,b).
Nlrp3 / diabetic mice showed insulin levels similar to
Nlrp3 / non-diabetic mice (unpaired t-test; P¼ 0.17),
despite their increased glycemia levels. However, Casp1 /
diabetic mice presented a trend towards lower levels of insulin,
than Casp1 / non-diabetic mice (P¼ 0.057; Supplementary
Table 2). These results suggest that while the electrophysiological
improvement observed could not be related to the rescue of the
insulin levels in the Casp1 / diabetic mice, we cannot exclude
that insulin could be also involved in the electrophysiological
improvement observed in Nlrp3 / diabetic mice. Both heart
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shows values from individual cell preparations, where horizontal bars represent means and error bars, s.e.m. # and ### represents, respectively, Po0.05
and Po0.001 (unpaired t-test). *, ** and **** represent, respectively Po0.05, Po0.01 and Po0.0001 (Bonferroni’s post test following one-way ANOVA).
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weight/body weight or heart weight/tibia length ratios were
similar among study groups (Supplementary Table 2). The
absence of NLRP3 or Casp1 prevented DM-induced QTc (Fig. 6c)
and AP prolongation (Fig. 6d,e). Importantly, Nlrp3 / and
Casp1 / diabetic mice had lower arrhythmia vulnerability and
severity in response to Caff/Dobu challenge when compared with
diabetic WT mice (Fig. 6f,g). The Nlrp3 / and Casp1 /
non-diabetic mice showed cardiac electrical profile similar to WT
non-diabetic mice (Supplementary Fig. 10a–e). Since the lack of
NLRP3 prevented DM-induced cardiac changes, we tested next
whether NLRP3 inhibition could reverse diabetes-induced cardiac
electrical disturbances (Fig. 6h). The IL-1b release inhibitory
compound CRID3 (CP-456773 (refs 36,37), renamed MCC-950)
is found to inhibit the NLRP3 inflammasome by unknown
mechanisms35. After 15 days of treatment, MCC-950 did not
interfere with high glucose levels and reversed the prolongation
of QT and QTc intervals in WT diabetic mice (Fig. 6i–k and
Supplementary Fig. 10f,g). This was fully in accordance
with the electrical vulnerability testing, as mice treated with
MCC-950 had significantly lower arrhythmia vulnerability and
severity compared with saline-treated WT diabetic control
mice (Fig. 6l,m). Thus, activation of the NLRP3 inflammasome
is required for diabetes to induce prolonged QTc and
arrhythmias.
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IL-1b has a key role in susceptibility to arrhythmias. In order to
unequivocally prove that IL-1b is responsible for DM-induced
cardiac electrical changes, we induced DM in IL-1r / mice
(Fig. 7a). IL-1r / developed hyperglycemia and lower insulin
levels in response to streptozotocin (unpaired t-test; P¼ 0.0001
and P¼ 0.04 respectively; Supplementary Table 3; Fig. 7b), but in
the absence of IL-1r no prolongation of QT (Supplementary
Fig. 11a) and QTc intervals after DM induction (Fig. 7c) could be
observed. Likewise, IL-1r / mice were less susceptible to
arrhythmia induction after the Caff/Dobu challenge (Fig. 7d,e).
No differences in body weight/cardiac weight as well as the heart
weight/tibia length ratios were observed between IL-1r /
diabetic and non-diabetic mice (Supplementary Table 3).
These results strongly indicate that IL-1b signalling has a key
role in the cardiac electrical disturbances observed in DM. We
thus sought to explore potentially therapeutic effects of IL-1
receptor antagonist (IL-1Ra) to rescue the electrical cardiac
function in diabetic WT mice. After 15 consecutive days of
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IL-1Ra (Anakinra) administration (10mg kg 1 per day
intraperitoneal (i.p.)), even under sustained hyperglycemic state,
diabetic IL-1Ra-treated mice presented much shorter QT and
QTc intervals than non-treated diabetic mice (Fig. 7f–j—This
experiment shares the same control group as Fig. 6h–k—and
Supplementary Fig. 11). In addition, the IL-1Ra-treated diabetic
mice showed lower arrhythmia vulnerability upon the Caff/Dobu
challenge (Fig. 7k,l).
Streptozotocin
0 5 60Time (d)
An
aly
se
s
Wild type (WT)
Casp1–/–
Nlrp3 –/–
AP
D
90
 
(m
s)
50
 m
V
0.
2 
m
V
WT + DM
Nlrp3 –/– + DM
Nlrp3 –/– + DM
Casp1–/– + DM
Casp1 –/– + DM 4
3
2
1
0
100
60
20
Ar
rh
yt
hm
ia
 s
co
re
WT
DM
Nlrp3 –/–
*
*
Casp1–/–
Caff/Dobu
STZ MCC950 treatment
Analyses
0 5 60 75Time (d)
Wild type (WT)
DM
WT Nlrp3 –/– Casp1–/–
50 ms
1 s
a
G
lu
co
se
 (m
g d
l–1
)
QT
c 
in
te
rv
al
 (m
s)
600
300
0
Control
*
*
DM
DM
WT Nlrp3 –/– Casp1 –/–
WT Nlrp3 –/– Casp1–/–
150
100
50
0
b c
d e
g
h
i
l
100
50 Pre Post Pre Post
QT
c 
in
te
rv
al
 (m
s)
QT
c 
in
te
rv
al
va
ria
tio
n 
(%
)
G
lu
co
se
 (m
g d
l–1
) 600
300
0
Pre Post
Saline
Saline
Saline
Saline
Saline
VT
0.
2 
m
V
MCC950
MCC950
MCC950
MCC950
Ar
rh
yt
hm
ia
 s
co
re
*
#
MCC950
Caff/Dobu
40
0
–40
4
3
2
1
0
kj
m
f
1 s
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13344 ARTICLE
NATURE COMMUNICATIONS | 7:13344 |DOI: 10.1038/ncomms13344 | www.nature.com/naturecommunications 9
Discussion
Diabetic patients often suffer of associated cardiovascular
diseases, such as increased susceptibility to ventricular arrhyth-
mias and sudden cardiac death. The mechanistic link between
DM and arrhythmias, however, remains unknown. Here we
dissected the complex signalling pathways involving different cell
types present in the diabetic heart. DM induces a sterile
inflammation that activates TLR2 and the NLRP3 inflammasome
in heart macrophages to produce IL-1b. In cardiomyocytes, IL-1b
then induces AP prolongation (through a decrease in Ito current)
and an increase in Ca2þ sparks resulting in increased electrical
vulnerability to arrhythmias. In the absence of TLR2, NLRP3,
Caspase 1 or IL-1r, DM fails to sensitize rodents to ventricular
arrhythmias. In addition, treatment with either MCC-950
(NLRP3 inhibitor) or anakinra (IL-1ra) reverses the cardiac
electrical remodelling and decreases the incidence of arrhythmias,
emphasizing the pathomechanistic relevance of IL-1b and
also a novel pharmacological strategy for the treatment of
DM-associated arrhythmias.
The activation of the inflammasome and the secretion of
IL-1b seem to be a major danger-sensing pathway to sterile
inflammation and cardiac repair in several heart diseases38.
Earlier studies have demonstrated activation of the NLRP3
inflammasome and increased expression of IL-1b in both type 1
(ref. 39) and type 2 (refs 40,41) diabetes (T1D and T2D), but until
now their relevance in the pathogenesis of diabetic heart disease
has been unknown. Herein we show that genetic deletion of
TLR2, NLRP3, Casp1 or IL-1r is sufficient to prevent both QTc
prolongation and increased susceptibility to arrhythmias. Our
results suggest that DM-triggered TLR2 activation induces the
expression of pro-IL-1b and the NLRP3 activation in heart
macrophages, thus promoting pro-IL-1b cleavage to a mature
form by Casp1 resulting in IL-1b secretion. Then IL-1b acts on
cardiomyocytes to prolong the AP and to increase Ca2þ sparks,
sensitizing hearts to arrhythmias. Although the endogenous TLR2
agonists and NLRP3 activators in our T1D model are not
precisely known, hyperglycemia is the most likely suspect to
trigger IL-1b production, since it is able to activate monocytes
through TLR2 to produce IL-1b12,42. The intermediary steps
from hyperglycemia to TLR2 and NLRP3 activation may involve
the release of endogenous TLR2 ligands43 and the generation
of oxidative stress44. The increase in both TLR2 and IL-1b
expression in diabetic patients45–47 suggests that this mechanism
of sterile inflammation is active in the natural course of disease.
A protective effect of TLR2 deficiency in DM has previously
been observed by others20, as well as the role of TLR2 activation
in the induction of arrhythmic events in an ischemia/reperfusion
animal model21. The close association between TLR2 activation
and IL-1b secretion and their influence on arrhythmogenesis
indicates that TLR2 and IL-1b are part of an inflammatory
pathway that has a major role in the pathogenesis of diabetes-
associated electric dysfunction of the heart.
The absence of insulin signalling can reduce Ito current,
resulting in AP and QT prolongation48. Nevertheless, the
circulating insulin levels in diabetic IL-1r / were significantly
decreased compared with non-diabetic counterparts, while a
strong trend towards decreased levels was found in diabetic
Tlr2 / and Casp1 / mice, even though it was not statically
different. Only diabetic Nlrp3 / mice presented circulation
insulin levels similar to non-diabetic controls. Although we
cannot exclude the possibility that preserved circulating insulin
levels account for the prevention of electrophysiological
abnormalities in diabetic Nlrp3 / mice, this is certainly not
the case in IL-1r / , Tlr2 / and Casp1 / mice. These
results reflect the limitation of our study where the systemic and
local anti-inflammatory effects in the KO animals are not
discernable using our global KO mice models.
The source of IL-1b production in vivo has been elusive in
disease models in which inflammasome activation has a
major pathophysiological role. In T1D patients, monocytes
spontaneously secrete IL-1b49, indicating that macrophages may
represent such a source. Our results show that depletion of
macrophages from cardiac muscle strips not only prevented TLR2
activation-induced IL-1b release, but also the Pam3/TLR2/IL-1b-
induced prolongation of the cardiac AP, pointing to macrophages
as the source of IL-1b secretion. We also show increased
NLRP3 content inside cardiac macrophages of WT diabetic
mice compared with Tlr2 / diabetic mice, demonstrating that
macrophage inflammasomes are activated in vivo.
The direct effects of IL-1b on electrical function of
cardiomyocytes reported in the literature are scant. A recent
review50 on this subject highlights the rather indirect evidences
linking IL-1, TNF and IL-6 to delayed repolarization, long QT
syndrome and ventricular tachycardia. In 1993, IL-1 (not the
mature IL-1b) was shown to increase the duration of the AP51 .
Another study described acute effects of IL-1b on atrial
preparations, and did not find any effects on APD52. Herein we
demonstrate that IL-1b creates a pro-arrhythmic environment
both in rodent and human cells by reducing the repolarizing Kþ
current (Ito), by increasing CaMKII oxidation/ phosphorylation
and Ca2þ spark frequency. A prolongation of the cardiac AP due
to lower Ito current has been described in diabetic experimental
models53,54 and in agreement with these data, we show here that
binding of IL-1b to its receptor in the heart can produce similar
effects. Hyperglycemia was previously reported to enhance
CaMKII-dependent activation of spontaneous SR Ca2þ release
events29. We also provide evidence that IL-1b increases both
Ca2þ spark frequency and loss of SR Ca2þ content during rest in
cardiac cells, indicating enhanced SR Ca2þ leak. Moreover,
although the possibility that IL-1b could promote oxidation and
activation of CaMKII has not been explored in cardiac tissue,
recent evidence suggests that this could be achieved via MyD88
inflammatory signalling31. Since the IL-1b receptor uses MyD88
as a signalling adaptor and we illustrate that IL-1b promotes
Figure 6 | DM-induced cardiac electrical alterations are regulated by the NLRP3 inflammasome. (a) Experimental protocol: diabetes induction in WT,
NLRP3 knockout (Nlrp3 / ) and Casp1 knockout mice (Casp1 / ). (b) Fasting blood glucose levels at day 60 (n¼WTþDM: 10; Nlrp3 / þDM: 8;
Casp1 / þDM: 10). (c) Corrected QT (QTc) interval duration (n¼WTþDM: 10; Nlrp3 / þDM: 8; Casp1 / þDM: 6). (d,e) Representative action
potential (AP) traces (left panel) and APD90 data (right panel) from the endocardial layer of left ventricle strips at 300ms basic cycle length (BCL)
stimulation (n¼WTþDM: 7; Nlrp3 / þDM: 5; Casp1 / þDM: 5). (f) Representative traces of arrhythmic vulnerability test induced by Caff/Dobu
showing normal ECGs in Nlrp3 / þDM and Casp1 / þDMmice (n¼WTþDM: 7; Nlrp3 / þDM: 7; Casp1 / þDM: 9). (g) Score quantification
of arrhythmia incidence and severity in diabetic groups. (h) Experimental protocol for MCC-950 treatment (50mg kg 1 i.p./daily/15 consecutive days).
(i) Fasting blood glucose levels pre (day 60) and post (day 75) treatment from at least four mice per group. (j,k) QTc interval values and per cent variation
pre (60 days) and post (75 days) treatment with saline or MCC-950. (l) Caff/Dobu test showing ventricular tachycardia (VT - see red line) in WTþDM
treated with saline, but not when treated with MCC-950. (m) Arrhythmia score summary after MCC-950 treatment (n¼ Saline: 6; MCC-950: 4). The
results are expressed as mean±s.e.m. Scatter plot shows values from individual mice, where horizontal bars represent means and error bars, s.e.m.
* Represents Po0.05 versus WTþDM (unpaired t-test). # represent Po0.05 (Bonferroni’s post test following two-way ANOVA.
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Figure 7 | IL-1b regulates cardiac electrical remodelling and cardiac arrhythmias. (a) Experimental protocol of diabetes induction in WTand IL-1 receptor
knock-out mice (IL-1r/ ). (b) Fasting blood glucose levels at day 60 (c) Corrected QT (QTc) interval duration (n¼WT: 10; lL-1r/ : 4; WTþDM: 10; IL-
1r/ þDM: 5). (d) Representative traces of arrhythmic vulnerability test induced by Caff/Dobu showing a normal ECG in IL-1r/ þDM mice.
(e) Score quantification of arrhythmia incidence and severity (n¼WT: 7; lL-1r/ : 4; WTþDM: 7; IL-1r/ þDM: 5). (f) Experimental protocol for IL-1ra
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cent variation pre and post treatment (for control reference please check Fig. 6j). (k) Representative ECG traces of WTþDM mice treated with
IL-1ra during Caff/Dobu test, showing normal electrical function. (l) Arrhythmia score summary after IL-1ra treatment (n¼ saline: 6; IL-1ra: 8). The results
are expressed as mean±s.e.m. Scatter plot shows values from individual mice, where horizontal bars represent means and error bars, s.e.m. * and
** represents, respectively, Po0.05 and Po0.01 (unpaired t-test). ## represent Po0.01 (Bonferroni’s post test following two-way ANOVA).
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oxidation of CaMKII (oxi-CaMKII) and increased CaMKII
phosphorylation (p-CaMKII) in cardiac tissue, it is likely that
IL-1b acts through CAMKII to promote pro-arrhythmic effects.
QTc prolongation is an independent marker of increased
mortality in T1D patients55,56, and on resting electrocardiograms
(ECGs) it is closely associated with susceptibility to
tachyarrhythmias. We demonstrate that pharmacological
strategies of blocking either the IL-1 receptor or NLRP3
activation were both very effective in reversing QTc prolongation
and attenuating the vulnerability to Caff/Dobu induced
arrhythmias in our experimental DM model. As IL-1Ra has
already been successfully used to improve the control of T1D and
T2D57,58, it could be readily tested in DM patients undergoing
IL-1Ra clinical trials to reduce the electrical vulnerability of the
heart. Finally, the robust results obtained here using the NLRP3
inhibitor, MCC-950, open a new therapeutic avenue for T1D
induced cardiac arrhythmias, since it improves the cardiac
electrical profile, while keeping other inflammasomes involved in
the response to infectious diseases intact.
Methods
Animals and experimental protocol. This study was carried out in strict accor-
dance with the recommendations of the Guide for the Care and Use of Laboratory
Animals of the Brazilian National Council of Animal Experimentation
(http://www.cobea.org.br/) and Federal Law 11.794 (October 8, 2008). The pro-
tocols of the present study were approved by the Committees for Animal Care and
Use at the Federal University of Rio de Janeiro (under no.: 130/13, 131/13 and
102/15), and at the University of Campinas (no. 3658–1). Tlr2 / male and
female mice in C57BL/6a background were kindly provided by Prof. Sergio Costa
Oliveira at Federal University of Minas Gerais (Belo Horizonte, Brazil). Nlrp3 /
(Genentech, USA) (# OM-214220) (ref. 17), Casp1 / (refs 59,60) (MTO #
14865) and IL-1r / mice (Jackson, USA) were generated in the C57BL/6
background. Also, male transgenic mice with cardiomyocyte-delimited transgenic
expression of either a CaMKII inhibitory peptide (AC3-I) or a scrambled control
peptide (AC3-C) were used32. Wild-type (WT) C57BL/6 male and female mice
were used as controls. Animals, studied at the age of 8–10 weeks, were kept at
constant temperature (23 C) in a standard light/dark cycle (12 h/12 h) with free
access to standard chow and water. Animals were divided in four groups: (a)
control non-diabetic mice (WT); (b) diabetic mice (WTþDM); (c) non-diabetic
transgenic mice (Tlr2 / , Casp1 / , Nlrp3 / , IL-1r / ); and (d) transgenic
diabetic mice (Tlr2 / þDM, Casp1 / þDM, NLRP3 / þDM,
IL-1r / þDM). The mice were bred and maintained under specific pathogen-
free conditions at the animal facilities of the Federal University of Rio de Janeiro,
and the mice were killed by cervical dislocation. Diabetes was induced by five
consecutive injections of (50mg kg 1 i.p.) streptozotocin61 (Sigma-Aldrich) in
0.05M citrate buffer (pH 4.5). For in vitro and ex vivo experiments the following
compounds were used: TLR2/TLR1 agonist (Pam3CSK4 InvivoGen, USA,
(1mgml 1)), rat recombinant IL-1b (Cat.# 400-01B PeproTech, USA,
(10 ngml 1)) human recombinant receptor antagonist (IL-1ra) (PeproTech, USA,
(100 ngml 1)). Commercial IL-1ra (Anakirna, Kineret, Swedish Orphan
Biovitrum, Sweden)62 and NLRP3 inhibitor (MCC950, Avistron Chemistry
Services, UK)35. In some specific experiments 8–12 weeks old male Wistar rats
were used.
Heart-to-body weight and heart-to-tibia length ratios. Mice were weighted
before killing and excised hearts were washed with PBS. Hearts were drained by
gentle squeeze using cotton gauze before weighing. Right tibias were gently excised
and all muscle was removed in order to expose the whole bone for precise
measurements with caliper rule.
Blood glucose and insulin concentration. Blood glucose levels were determined
using a glucose reagent strip and a standard automated glucometer (AccuChek
Advantage II, Roche, Ireland). Briefly, animals were fasted for 5 h and blood was
obtained from the tip of the tail vein of the fully awake, non-anesthetized animals.
Mice were considered diabetic if fasting glycemia was higher than 300mg dl 1.
Insulin levels were measured using a commercial Kit (ImmunoChem Coated
Tube—Insulin—MP Biochemicals, USA; Cat.# 07-260102).
Macrophage depletion. To deplete macrophages, Clodronate liposomes
(Clodronate-L) obtained from Clodronate Liposomes Foundation (The
Netherlands) and stored at 4 C were prepared as a suspension for intravenous
(tail vein) injection (10 ml g 1) as suggested by the manufacturer and previously
described33,63. As a control, PBS containing Liposomes (referred as Liposomes) was
used at the same final volume.
Histology and immunohistochemistry. After weighting the heart was cut
transversally, fixed in 4% formaldehyde, and embedded in paraffin. Five
micrometre thick sections were obtained and stained with Picrosirius red for
collagen content analysis according to standard protocols. Images were obtained
with an Axio Zoom.V16 microscope (Zeiss, Germany) and analysed with Image
Pro Plus Analyser 7 (Media Cybernetics, USA).
For immunostaining, hearts were dissected, fixed in 2% paraformaldehyde with
shaking, cryoprotected in 30% sucrose, and embedded in Tissue-Tek OCT (Miles
Laboratories, Pittsburgh, PA, USA). Ten micrometre thick sections were obtained
and collected serially onto polyethilenamide-coated glass slides. Before
immunolabelling, slides were extensively washed, permeabilized with 0.5% Triton
X-100 (Sigma-Aldrich), blocked with 5% bovine serum albumin (Sigma-Aldrich)
and finally incubated overnight at 4 C with primary antibodies. The following
antibodies were used: mouse monoclonal anti-troponin T (TnT; 1:100; Thermo
Fisher Scientific no. 13-11); goat polyclonal anti-CIAS1/NALP3 (NLRP3; 1:200;
Abcam no. ab4207); rabbit polyclonal anti-ASC (ASC; 1:200; Sigma-Aldrich no.
SAB4501315), and rat monoclonal anti-F4/80 (F4/80; 1:100; Abcam no. ab6640).
After rinsing sections were incubated for 2 h at room temperature with fluorescent
dye-conjugated anti-mouse, rat or rabbit antibodies (10mgml 1; Life
Technologies). They were then incubated with 4,6-diamidino-2-phenylindole for
10min at room temperature. After an additional wash with PBS and one with
distilled water, slides were mounted with mounting medium (Prolong). Negative
controls were obtained by omitting the primary antibody. Confocal images were
obtained in a Nikon A1 confocal laser scanning microscope using Plan Apo lambda
40 and 60 objectives for oil immersion (0.6 and 1.49 of numerical aperture,
respectively). Images correspond to renderized stacks. Stacks (images captured
0.3 mm apart in Z-plane) of XY images were collected, and to avoid bleed-through
between channels, images at each wavelength were captured sequentially. Images
were assembled, prepared for analysis uniformly and XY and XZ images were
generated using ImageJ software (NIH, USA). To reduce variability among samples
sections from different groups were processed simultaneously for each marker and
the setting for image acquisition was the same for all the images. The fluorescence
area (anti-NALP3) was measured using the ImageJ software (NIH, USA).
Flow cytometry. Hearts were thoroughly perfused with PBS, minced into 1mm3
fragments and digested with 1mgml 1 collagenase II (Worthington) in DMEM.
Fragments were submitted to 5–6 cycles of digestion under gentle agitation at 37 C.
The supernatant was collected after every cycle and stored in DMEM with 10% FBS.
Subsequently, samples were filtered through a 100mm strainer, washed with 0.5%
bovine sera-albumin (BSA) in PBS and submitted to Fc receptor blocking with
Mouse BD Fc Block (BD Biosciences, Cat# 553141) according to the manufacturer’s
instructions. The following primary antibodies were added directly to the blocked
samples and incubated for 30min at 4 C: CD45-PerCP (BD Biosciences, Cat#
557235 1:100), CD11b-FITC (BD Biosciences, Cat# 553310 1:100), F4/80-PE (BD
Biosciences, Cat# 563899 1:50), Ly6C-APC (BioLegend, Cat# 128003 1:25) and
MHCII-PE-Cy7 (BioLegend, Cat# 116419 1:100). Samples were washed and
incubated with 0.25mgml 1 4,6-diamidino-2-phenylindole for 5min at room
temperature. Data were acquired in BD FACSAriaIIu. The gating strategy was as
follows: CD45þ-doublet discrimination (FSC-H, FSC-W)-dead cell exclusion-
CD11bþ F4/80þ-morphology (SSC-A, FSC-A)-MHCIIhighLy6C
(Supplementary Fig. 8). Data were analysed using FlowJo v10 software.
Calcium transient and cell shortening measurement. Myocyte Isolation: rats
(200–350 g) were anaesthetized by isoflurane inhalation or an intra-peritoneal
injection of sodium pentobarbitone (35mg kg 1 body weight,), and hearts were
rapidly excised. Cardiac myocytes were isolated with collagenase digestion using a
previously described technique64. Briefly, the hearts were attached via the aorta to a
cannula, excised and mounted in a Langendorff apparatus. They were then
retrogradly perfused at 37 C at a constant perfusion pressure of 70–80mmHg
with Krebs-Henseleit solution (K-H) of the following composition (mM): 146.2
NaCl, 4.7 KCl, 1.00 CaCl2, 10.0 N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic
acid (HEPES), 0.35 NaH2PO4, 1.05 MgSO4 10.0 glucose (pH adjusted to 7.4 with
NaOH). The solution was continuously bubbled with 100% O2. After a stabilization
period of 4min, the perfusion was switched to a nominally Ca2þ -free K-H for
6min. Hearts were then recirculated with type 2 collagenase (118 units ml 1),
0.1mgml 1 protease and 1% BSA, in K-H containing 50 mM CaCl2. Perfusion
continued until hearts became flaccid (10–15min). Hearts were then removed from
the perfusion apparatus by cutting at the atria-ventricular junction. The isolated
myocytes were separated from the undigested tissue and rinsed several times with a
K-H solution containing 1% BSA and 500 mM CaCl2. After each wash, myocytes
were left for sedimentation during 10min. Myocytes were kept in K-H solution at
room temperature (20–22 C) until use. After isolation, cells were incubated for
24 h at 4 C in modified KB solution (containing: 70mM potassium gluconate,
10mM KCl, 20mM taurine, 1mM MgCl2, 10mM glucose, 10mM HEPES; 0.3mM
EGTA; pH 7.4) in the presence or absence of 10 ngml 1 IL-1b and/or 2.5 mM of
the CaMKII inhibitor KN93. EGTA was omitted from the solution in the
experiments in which the cytosolic Ca2þ concentration ([Ca2þ ]i) was quantitated.
Cells from the same heart were used for incubation with and without IL-1b
(10 ngml 1) for 24 h at 4 C. For ([Ca2þ ]i) measurement, myocytes were loaded
with 10mM indo-1 AM (Molecular Probes, USA) during 15min at room
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temperature. The perfusion chamber containing the cells was placed on the stage of
an inverted microscope (Nikon Diaphot 200) coupled to a microfluorimetry system
(Photon Technology Intl, Inc.). The dye was excited at 360 nm, and the emission
ratio at 410 and 485 nm was converted to [Ca2þ ]i according to Bassani et al.64,
using calibration parameters determined in live cells. Myocyte contractile activity
was evaluated simultaneously by monitoring peak cell shortening (expressed as per
cent of resting cell length) under electrical stimulation at 1Hz. The propensity to
develop arrhythmias was estimated from the number of non-stimulated contractile
events (NSE), which were defined as the spontaneous contractions developed after
interruption of a 10min-long stimulation train at either 0.5 or 3Hz. To investigate
the role of a possible increase in Ca2þ extrusion rate via the Naþ /Ca2þ exchanger
(NCX) as a factor that may facilitate the generation of Ca2þ -dependent
spontaneous electrical activity, the ratio of the rate constants of [Ca2þ ]i decay at a
caffeine-evoked transient and a twitch (in which cytosolic [Ca2þ ]i removal is
mainly attributable to the NCX and the SR Ca2þ -ATPase, respectively), was
compared in control and IL-1-treated myocytes64. To estimate the rest-dependent
loss of the SR Ca2þ content, which may occur in case of increased rate of diastolic
SR Ca2þ release25, the content of Ca2þ stored in the SR (as Jmoles Ca2þ per liter
of non-mitochondrial cell water) at steady-state was estimated from a Ca2þ
transient evoked by caffeine in Naþ -, Ca2þ -free solution26 after stimulation at
1Hz for 3min. The protocol was repeated with interposition of a 2min-long rest
period before caffeine application. The variation in SR Ca2þ load per min of rest
was calculated based on the difference of the load in the steady-state (that is,
non-rested) and post-rest conditions. For detection of spontaneous Ca2þ release
myocytes were loaded with 10 mM of Fluo-3 AM (Molecular Probes) and mounted
on the stage of a Zeiss 410 inverted confocal microscope (LSMTech, USA). Cells
were imaged in linescan mode along their long axis, with excitation via the 488 nm
line of an argon laser emission was collected at4515 nm. Each image consisted of
512 line scans obtained at 4ms intervals. Data were analysed using the
‘Sparkmaster’ plugin for ImageJ (NIH, USA). Sparks were imaged in quiescent cells
after 10min stimulation at either 0.5 or 3Hz.
Western blot. Left ventricle tissue samples were incubated for 24 h in the presence
or absence of 10 ngml 1 IL-1b and subsequently homogenized. Protein was
measured by the Bradford method using BSA as standard. Lysates (B90mg of total
protein per gel line) were seeded in a 10% SDS polyacrylamide gel and transferred
to polyvinylidene difluoride membranes. Blots were probed overnight with
antibodies raised against oxidized CaMKII (referred as Ox-CaMKII), Cat# 07-1387,
1:1,000 (Millipore Corp, USA). After stripping the blots were probed with
phospho-Thr286-CaMKII (referred as p-CaMKII), Cat# 32678 1:1,000 (Badrilla,
UK), Anti IL-1b Cat# I3767 1:1,000 (Sigma, USA) and Anti GAPDH, Cat#
MAB374, 1:2,000 (Santa Cruz Biotechnology, USA) was used for normalization.
Immunoreactivity was visualized by a peroxidase-based chemiluminescence
detection kit (Amersham Biosciences) using a Chemidoc Imaging System. The
signal intensity of the bands in the immunoblots was quantified by densitometry
using the Image J software (NIH, USA).
Magnetic resonance images. In vivo magnetic resonance cardiac imaging (MRI)
was performed on a 7.0 T horizontal-bore MR scanner (Varian Inc, USA) under
inhalation anesthesia via a nose cone (isoflurane 1.5 vol% supplemented by 0.5 liter
oxygen per minute). Rectal temperature was monitored, and body temperature was
kept constant at 36.5 C through an air heating system. The ECG was recorded at
two precordial subcutaneous electrodes leads and respiration was monitored with a
pneumatic pillow. Measurements were transmitted through a monitoring and
gating system (model 1025 Monitoring and Gating System; SA Instruments, USA)
to the MRI system. High-resolution bright-blood MRI experiments were conducted
using an ECG-triggered fast spoiled gradient echo cine sequence in a number of
adjacent short- and long-axis slices. The scanning parameters were optimized for
the signal-to-noise ratio as follows: flip angle¼ 30, echo time (TE)¼ 1.9ms,
repetition time (TR) DR-R interval, RF pulse width¼ 1.0ms, number of
averages¼ 8; 15 frames per heart cycle were obtained. All images were acquired
with a field of view of 30 30mm and a data matrix of 128 128mm to yield an
in-plane resolution of 234 mm2. Total scan time was in the range of 25min. Each
imaging protocol resulted in five to seven 1mm thick short-axis images covering
the whole heart from apex to base with no gap between slices. The data were
analysed with Osirix Imaging software. Ventricular slice volumes were determined
from end-diastolic and end-systolic images by multiplication of the compartment
area and slice thickness. Total volumes were calculated as the sum of the volume of
all slices and the ejection fraction was calculated by Simpson’s rule.
ECG and arrhythmia incidence/severity test. ECG recording was carried out in
conscious animals with a noninvasive method65. Electrodes were positioned in the
DI lead and connected by flexible cables to a differential AC amplifier (model 1700,
A-M Systems, USA), with signal low-pass filtered at 500Hz and digitized at 1 kHz
by a 16-bit A/D converter (Minidigi 1-D, Axon Instruments, USA) using Axoscope
9.0 software (Axon Instruments, USA). Data were stored for offline processing. For
the analysis of percentage variation of the QTc interval, the following calculation
was applied: ((Vf-Vi)/Vi 100) where Vf¼ Final value (after the treatment) and
Vi¼ Initial value (before the treatment).
To perform the arrhythmia vulnerability test, anesthetized animals (Xilazine—
Syntec, Brazil, (0.5mg g 1)) and ketamine—Crista´lia, Brazil, (1.5mg g 1))
received an injection of caffeine (120mg kg 1, i.p.) and dobutamine (50 mg kg 1,
intravenous)29. A basal ECG was recorded for 3min before caffeine/dobutamine
application. After the treatment, the ECG was recorded for 15min. An adapted
arrhythmic score of incidence and severity was applied to each animal29,66: 0 if
there were no arrhythmic events during the test; 1, if one premature ventricular
contractions were present; 2, if bigeminy and/or salvos were present; 3, for
ventricular tachycardia; 4, in case of ventricular fibrillation; and 5, in case of
spontaneously induced ventricular fibrillation.
Cardiac action potential recording. APs were recorded from murine left ven-
tricular muscle strips. The cardiac strips were immobilized at the bottom of a tissue
dish exposing the endocardium67. The preparations were superfused with Tyrode’s
solution containing (in mM): 150.8 NaCl, 5.4 KCl, 1.8 CaCl2, 1.0 MgCl2, 11.0
D-glucose, 10.0 HEPES (pH 7.4 adjusted with NaOH; 37.0±0.5 C) saturated with
oxygen at a perfusion flow rate of 5mlmin 1 (Miniplus 3, Gilson, France). The
tissue was stimulated at three different basic cycle lengths (200, 300 and 500ms).
Transmembrane potential was recorded using glass microelectrodes (10–40MO
DC resistance) filled with 2.7M KCl connected to a high input impedance
microelectrode amplifier (Electro 705, World Precision Instruments, USA).
Amplified signals were digitized (1,440 digidata A/D interface, Axon Instrument,
Inc.) and stored in a computer for later analysis using LabChart 7.3 software
(ADInstruments, Australia). The following parameters were analysed: resting
membrane potential, action potential amplitude and APD at 90% (APD90)
repolarization. For specific set of experiments left ventricular muscle strips, from
Wistar rats were incubated for 24 h at 4 C with Tyrode’s solution containing
agonist or not as previously described68.
Transient outward potassium current (Ito) recording. Immediately after isola-
tion, rats cardiomyocytes were suspended in modified KB solution containing
human recombinant IL-1b (PeproTech, USA, (60 pgml 1)) or not (control group)
and incubated in this solution at 4 C for 24 h. Cells were transferred to a shallow
chamber and allowed to settle for at least 10min before superfusion with the
external bathing solution. For the experiments we used only Ca2þ -tolerant
rod-shaped cells, with clear cross-striations and lacking any visible blebs on their
surface. All experiments were performed at room temperature (20–22 C). Ion
currents were recorded using the whole-cell configuration of the patch-clamp
technique with an Axopatch 200B amplifier (Axon Instruments Inc., USA).
Recording pipettes were obtained from borosilicate tubes (Sutter Instruments,
USA), and had a tip resistance of 1–3 MO when filled with the internal solution
(in mmol l 1): L-aspartic acid (potassium salt) 80, KH2PO4 10, MgSO4 1, KCl 50,
HEPES-Kþ 3, ATP-Na2 3, EGTA-Kþ 10, pH adjusted to 7.2 with KOH. Following
the patch rupture, whole-cell membrane capacitance was measured from
integration of the capacitive transients elicited by voltage steps from  50 to
 60mV, which did not activate any time-dependent membrane current. Series
resistance was compensated by 80% in order to minimize voltage errors, and
checked regularly throughout the experiment. The voltage-clamp experimental
protocols were controlled with the ‘Clampex’ program of the ‘pClamp 10.2’
software (Axon Instruments Inc., USA). The external bathing solution was
(in mmol l 1): NaCl 86, MgCl2 1, HEPES-Naþ 10, KCl 4, CaCl2 0.5, CoCl2 2,
dextrose 12, TEA-Cl 50, pH adjusted to 7.4 with NaOH. Ito was recorded during
depolarizing pulses from - 30 mV to + 50 mV, starting from a holding potential of -
60mV (ref. 68). Pulses were applied at a frequency of 0.1Hz to ensure the full
recovery of Ito from inactivation. The TEA-resistant time-independent Iss was
digitally subtracted. Ito, considered as the peak current Ito minus Iss, was
normalized to cell capacitance, and expressed as pA/pF. Steady-state inactivation
was determined using a two pulse protocol consisting of a 5 s conditioning prepulse
ranging from  90 to þ 10mV in 10mV increments, followed by the 500ms test
pulse to þ 50mV. Peak current amplitude at þ 50mV was plotted against the
prepulse voltage. To study the time-dependent recovery of Ito, a 150ms
conditioning pre-pulse to þ 50mV to induce channel inactivation was followed by
a test pulse to þ 50mV, applied at increasing intervals.
Microelectrode array analysis (MEA). MEA measurements in cardiomyocytes
derived from induced pluripotent stem cells (iPS) (Cor.4U—Axiogenesis,
Germany) were performed 69. The cells were tested to mycoplasma detection
before use. Cardiomyocytes were detached with 0.05% Trypsin in 0.5mM EDTA
(Gibco/Life Technologies) for 5min at 37 C, centrifuged for 5min at 1,000 r.p.m.
and resuspended in Cor.4U Culture Medium. Then, 20,000 cells were plated in
each well of a 6-well MEA chamber (60-6wellMEA200/30iR-Ti-tcr, Multi-Channel
Systems, Germany) coated with 0.01% fibronectin (Sigma-Aldrich). After 72 h, the
Cor.4U Culture Medium was replaced with Tyrode’s solution and field potentials
were recorded at a sampling rate of 10 kHz with the MC-Rack software at 37 C.
The FPD was manually measured from the minimum of the sharp negative
spike to the following maximum. For analysis of the per cent variation of FPD the
following calculation was applied: ((Vf-Vi)/Vi 100) where Vf¼ Final value
(after incubation with IL-1b, IL-1bþAIP or vehicle) and Vi¼ Initial value
(before incubation).
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Cytokine level measurements. Il-1b levels were measured using an
enzyme-linked immunosorbent assay kit according to manufacturer’s instructions
(R&D systems, USA)70.
Statistical analysis. For statistical analysis, the following tests (two-tailed) were
applied: Student’s t-test for comparisons between two groups in the case of one
independent factor; one-way analysis of variance (ANOVA) in the case of one
independent factor, when comparing more than two groups; two-way ANOVA in
the case of two independent factors, followed by the Bonferroni test for multiple
comparisons; in case of not normally distributed data, either Mann–Whitney test
or Kruskal–Wallis test followed by Dunn’s multiple comparisons was applied.
Po0.05 values were considered statistically significant. Data are presented as
mean±standar error of the mean (s.e.m.). All analyses were made using GraphPad
Prism 5.0 (GraphPad Software, USA). We did not use statistical methods to
predetermine sample size, there was no randomization designed in the experi-
ments, and the studies were not blinded. Samples sizes were estimated on the
basis of sample availability and previous experimental studies of the cardiovascular
system9–13,16
Data availability. The authors declare that the data supporting the findings of this
study are available within the article and its Supplementary Information Files or
from the corresponding authors upon reasonable request.
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